W has made over 2 trades of the Immunovant Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 49,766 units of IMVT stock worth $1,445,702 on 18 March 2019.
The largest trade he's ever made was exercising 49,766 units of Immunovant Inc stock on 18 March 2019 worth over $1,445,702. On average, W trades about 5,977 units every 96 days since 2015. As of 18 March 2019 he still owns at least 59,766 units of Immunovant Inc stock.
You can see the complete history of Mr. Middlekauff stock trades at the bottom of the page.
W. Bradford (Brad) Middlekauff serves as General Counsel of the Company. From October 2015 to April 2019, he served as Senior Vice President, General Counsel and Secretary of PDS Biotechnology Corporation (formerly known as Edge Therapeutics, Inc.), a publicly traded biotechnology company. From October 2014 to October 2015, Mr. Middlekauff was Executive-in-Residence at Princeton University. From December 2008 to August 2013, Mr. Middlekauff was Chief Legal Officer, General Counsel and Secretary at Kolltan Pharmaceuticals, Inc., where he also ran the business development function. From March 2000 to April 2008, he was Senior Vice President, General Counsel and Secretary of Medarex, Inc., a publicly traded biotechnology company. Mr. Middlekauff previously served on the Board of Directors of ProteoDesign, S.L., a privately-held biotechnology company based in Barcelona, Spain.
W Middlekauff is 59, he's been the General Counsel of Immunovant Inc since 2019. There are 4 older and 11 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
W's mailing address filed with the SEC is 320 W 37TH STREET, 3RD FLOOR, , NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann oraz Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: